Sandoz Canada, a unit of Novartis’ generics arm, has opened a second manufacturing plant at its site in Boucherville, Quebec, boosting local production capacity 66 per cent.
in-PharmaTechnologist.com’s latest round up of products launched in the pharmaceutical manufacturing sector includes new offerings from Genevac, Lock and AdvantaPure.
Gene therapy could be advanced by a worm more commonly associated with causing a deadly parasitic disease, according to researchers presenting at the British Pharmaceutical Conference (BPC).
Haupt Pharma has completed its merger with fellow German companies Amareg and Wülfing Pharma to create a major new force in the European contract development and manufacturing sector, with around 1,500 staff and an annual turnover of €180m.
Indian pharmaceutical firm Alembic is seeking to expand its presence in the lucrative US and European drug markets through an expanded partnering programme.
in-PharmaTechnologist.com’s latest round up of developments in contract manufacturing includes Therapure’s launch and facility expansions by Hollister-Stier, West and Dow.
Beleaguered life science tools and services company MDS Inc, has recorded disappointing third quarter results, with revenues from its Analytical Technologies and MDS Pharma Services divisions missing forecasts.
eClinical specialist Phase Forward has added to its portfolio by purchasing interactive-response technology company Clarix for $40m in cash in a move aimed at toppling ClinPhone from its leading position in the sector.
The second round of bids for Elan Drug Technologies (EDT) is expected to be received by mid-September, with a sale price of up to $1.4bn mooted in press reports.
US fine and industrial chemicals specialist Aceto says that its expansion on the global stage, particularly in Europe and Asia, is starting to pay financial dividends.
Despite a decade-long build up, drugmakers are yet to wake up to the “no data, no market” mantra of the EC’s REACH legislation, according to SAFC’s marketing director Amanda Halford.
UK researchers have developed two synthetic molecules that coax stem cells to differentiate into either neurons or epithelial cells for use in drug discovery applications.
Tocris Bioscience has launched a new search facility that enables researchers to search for chemicals by the biological targets they work on, rather than the chemical name itself.
UK analytical services expert, Quotient Bioscience has received a significant equity investment from TA Associates to help further the firm’s acquisition-led and organic growth strategy.
Canada’s Patheon put in another quarter of robust revenues growth in its third quarter, which coupled with cost-reduction measures helped the firm trim its net loss to $14.7m, down 75 per cent on a year ago.
Growth in licensing deals between large drugmakers companies and their smaller, research-based counterparts continued apace in 2007, but the average total value of each deal has started to fall.
Recent developments in the clinical research sector include an acquisition by Canada’s Algorithme, a Dutch CRO looking to push into the North American market, and a £20m boost for UK clinical research.
Drug delivery specialist BioAlliance Pharma says that its decision to focus on the oncology and infectious disease markets helped it reduce its half-year 2008 losses.
US fine chemical company Sigma-Aldrich said this morning that subsidiary SAFC Pharma has kicked off a $30m expansion plan for its active high-potency pharmaceutical ingredient (API) manufacturing facility in Madison, Wisconsin.
Caliper Life Sciences has launched two new kinase profiling services as well as new assay kits that aim to provide researchers with a better understanding of their kinase inhibitor drug candidates.
in-PharmaTechnologist.com's periodic round-up of developments and deals in the pharmaceutical manufacturing space, includes news on 3M and Ligacon, Dishman, Stiefel and Barrier and Forbes.
UK and Swedish researchers have developed a system that eliminates the need for antibiotics and resistance genes in the engineering of biopharmaceutical products, making the process both safer and less costly.
bioMerieux hopes that its new specially-packaged growth media products will help it “clean up” in the pharmaceutical industry’s lucrative sterility testing market
UK-based polymer technology specialist Chromatide and Akzo Nobel's Separation Products (SP) unit are teaming to develop a HPLC media for purification applications in the drug manufacturing industry.
Japan’s Shionogi is paying $1.4bn (€959m) for US drugmaker Sciele Pharma as part of a plan to strengthen its sales position in the country’s $286bn a year drug market.
Merck & Co has been accused of carrying out clinical trials of its Vioxx (rofecoxib) painkiller that were designed primarily for marketing purposes rather than to answer a clinical hypothesis.
Contrary to fears, the European Union’s Clinical Trials Directive has not had an inhibitory effect on the number of studies carried out by publicly-funded researchers, at least in Denmark.
Contract services firm Marksans Pharmaceutical says that the RPS 1bn (€15.4m) acquisition of UK generics group Relonchem will expand its distribution network and build its presence in the European market.
US trial firm ACRI and contract research organisation (CRO) Clinesian have teamed up to target the pharmaceutical sector’s ever growing demand for integrated clinical development capacity.
Canada’s PharmEng International almost tripled its turnover in the second quarter, as its acquisition of a Pfizer manufacturing facility at the end of 2007 transformed sales at contract manufacturing facility Keata Pharma.
A milestone payment from Bristol-Myers Squibb for the successful advancement of a project into clinical development, along with strong sales by its contract research and manufacturing services unit, prompted Albany Molecular Research Inc (AMRI) to hike...
Oxford Diffraction has launched a new dual wavelength X-ray diffractometer that promises to determine the structure of molecules in even the most challenging of crystal samples.
Hungarian researchers have developed a new bioinformatics tool that can identify and correct abnormal, incorrect and mispredicted protein annotations in public databases.
Japanese scientists have derived ‘embryonic’ stem cells from tissue taken from discarded human wisdom teeth, potentially bypassing the ethical dilemma of taking them from embryos.
Contract research organisation Chiltern International has finalised the reorganisation of its early-stage clinical development activities, following its acquisition of Drug Development Solutions in February.
UK laboratory services firm LGC has brought the first BioMark system into the UK in order to accurately quantify rare gene sequences for its pharmaceutical customers.
Exclusive interview with Bilcare CSO Dr Praful Naik
Executives in pharmaceutical companies tasked with implementing an anti-counterfeiting strategy already have a difficult job assessing a frankly bewildering array of technological solutions.
Codexis and Arch Pharmalabs’ expanded supply and development deal will see the latter produce APIs used in the manufacture of atorvastatin, principal component of Pfizer’s cholesterol buster Lipitor.
The Tel-Aviv District Court has found in favour of Sun Pharmaceuticals in its long running struggle to acquire Israeli drug and pharmaceutical ingredient maker Taro Pharmaceutical Industries.
The FDA says that Sandoz, the generics arm of Swiss drug major Novartis, failed to validate manufacturing processes used to produce metoprolol succinate ER tablets at its plant in Wilson, North Carolina.
A facility operated by fatty acid specialist Equateq on the island of Lewis in Scotland has met with UK good manufacturing practice (GMP) standards for the production of lipid-based APIs for the drug industry.